Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Funding the Future: The Capital Sources Fueling AI

    Investment Banking’s Anu Sharma and Jim O’Connor discuss potential sources, incentives, and implications for AI capital formation.

    Read more

  • Auto Insurance in Transition: Competition, Pricing, and the Rise of AI

    Adam Klauber, William Blair’s group head of financial services and technology research, sits down with Bill Daniel, CEO of AWL, to explore how the U.S. auto insurance market is evolving after an extended hard market.

    Watch the podcast

  • Women Founders Forum: Building with Purpose, Scaling With Intention

    William Blair’s Women Founders Forum brought together a mix of emerging and established founders, operators, and investors for an afternoon of candid conversation, insights, and meaningful connection.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures